Asia-Pacific Acute Myeloid Leukemia Treatment Market Size

Asia-Pacific Acute Myeloid Leukemia Treatment Market Analysis

The Asia-Pacific Acute Myeloid Leukemia Treatment Market size is estimated at USD 338.96 million in 2024, and is expected to reach USD 517.24 million by 2029, growing at a CAGR of 6.46% during the forecast period (2024-2029).

COVID-19 had a significant impact on the Asia-Pacific acute myeloid leukemia (AML) treatment market during the initial phases owing to factors such as limited supply and sales of medicines, restrictions on the import and export of therapeutics, and shortage of AML medicines all over Asia. Moreover, COVID-19 worsened the AML patient's overall healthcare. For instance, as per an article published in September 2021 by the AML journal, patients with acute myeloid leukemia (AML) in India who received induction during the COVID-19 lockdown had a higher mortality rate than patients treated after the lockdown was lifted. However, the market gained its normal growth in the post-pandemic era due to the rise in product sales, product launches, and an increase in research and development focused on AML therapeutics.

Factors such as the high incidence and prevalence of acute myeloid leukemia and advancement in pharmacology and molecular biology to promote drug development in the Asia Pacific region are also anticipated to drive the market growth over the forecast period. For instance, according to 'Leukaemia in Australia statistics 2022', it was estimated that 5,202 new cases of leukemia were likely to be diagnosed in Australia (3,198 males and 2,004 females) in 2022. It was also estimated that a person had a 1 in 58 (or 1.7%) risk of being diagnosed with leukemia by the age of 85 (1 in 47 or 2.1% for males and 1 in 77 or 1.3% for females). Furthermore, government initiatives and funding for AML in the Asia Pacific region are likely to boost market growth. According to a 2022 update from the Department of Health and Aged Care, from 1st March 2022, Australians with acute myeloid leukemia (AML) were likely to have access to a new treatment option through the Pharmaceutical Benefits Scheme (PBS). Mylotarg (gemtuzumab ozogamicin) was listed for the first time for the treatment of patients with previously untreated de novo CD33-positive AML, for use in combination with standard intensive chemotherapy.

The market is also expected to benefit from continuous developments in pharmacology and molecular biology for the creation of innovative medicines. Pharmaceutical companies competing in the market are investing a lot of money in research programs to develop new solutions. These R&D initiatives are also blamed for the shortcomings of the acute myeloid leukemia medicines now on the market. For instance, in September 2021, INTAS launched Oral Azacitidine, a drug approved for use in maintenance therapy for adult patients with Acute Myeloid Leukaemia in India under the brand name Azadine-O.

Though market growth is expected, complications related to chemotherapy are expected to restrain it.